- Details
- Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the det...
|
- Details
- As we try to decrease the burden that bladder cancer patients face, the topic of deintensification of the management of low-risk, non-muscle-invasive bladder cancer has become more and more popular. The 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a session titled, Optimizing Personalized Management of Nonmuscle-Invasive Bladder Cancer. Angela Smith...
|
- Details
- In January 2020, pembrolizumab was approved for the treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected to not undergo cystectomy. In this conversation, Arjun Balar, MD, and Petros Grivas, MD, Ph.D. discuss the use of pembrolizumab in the real-world sett...
|
- Details
- Subtypes in non-muscle-invasive bladder cancer are not well-defined, whereas the molecular landscape of muscle-invasive bladder cancer is relatively well-established. During the optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Eugene Pietzak, MD, discussed the molecular landscape...
|
- Details
- Anne Schuckman, MD, MBBS, discusses which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy with Ashish Kamat, MD. What’s clinically difficult in high-risk non-muscle-invasive bladder cancer is that 50% of patients undergoing TURBT plus intravesical therapy have long-term recurrence-free survival, however, 20% will progress to muscle-invasive bladder ca...
|
- Details
- In this conversation with Ashish Kamat, Lars Dyrskjøt, an expert in the field of molecular markers and personalized medicine speaks about circulating tumor DNA and the potential as a tumor for guiding treatment decisions in bladder cancer. Cell-free DNA in the blood has a half-life of less than two hours, so it makes it possible to use it as a biomarker of the direct tumor burden and hence the det...
|
- Details
- Bernard Bochner joins Ashish Kamat in this discussion discussing the advancements throughout 2020 in muscle-invasive non-metastatic bladder cancer. It would be impossible to discuss the year without mentioning the impact of COVID-19. There are some diseases that can withstand treatment delay, but muscle-invasive bladder cancer is not one of those tumors. These challenges pushed the bladder cancer...
|
- Details
- Management decisions at presentation are critical for survival— a talk by Curtis A Pettaway, MD. Although primary urethral carcinoma (UC) is rare, with an incidence of 4.3 per million in men and 1.5 per million in women, recurrence is associated with distant metastases. Therefore, physicians will want to be alert to the possibility of UC when, for example, the patient has a urethral protrusion. Th...
|
- Details
- The Phase 3 data from the United States clinical trial evaluating an investigational gene therapy, nadofaragene firadenovec (rAd-IFN/Syn3), for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) was recently published in The Lancet Oncology. In this conversation with Dr. Ashish Kamat, Girish Kulkarni, MD discusses the k...
|
- Details
- In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...
|
